{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T18:14:19Z","timestamp":1793297659580,"version":"4.5.0"},"reference-count":36,"publisher":"Elsevier BV","issue":"11","license":[{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,1,22]],"date-time":"2022-01-22T00:00:00Z","timestamp":1642809600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jacc.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of the American College of Cardiology"],"published-print":{"date-parts":[[2022,3]]},"DOI":"10.1016\/j.jacc.2021.12.032","type":"journal-article","created":{"date-parts":[[2022,3,14]],"date-time":"2022-03-14T14:34:43Z","timestamp":1647268483000},"page":"1035-1046","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":216,"title":["Effect of Pelacarsen on Lipoprotein(a) Cholesterol and Corrected Low-Density Lipoprotein Cholesterol"],"prefix":"10.1016","volume":"79","author":[{"given":"Calvin","family":"Yeang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ewa","family":"Karwatowska-Prokopczuk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fei","family":"Su","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian","family":"Dinh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuting","family":"Xia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph L.","family":"Witztum","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sotirios","family":"Tsimikas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jacc.2021.12.032_bib1","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1111\/j.1365-2796.2012.02592.x","article-title":"Lipoprotein(a): resurrected by genetics","volume":"273","author":"Kronenberg","year":"2013","journal-title":"J\u00a0Int Med"},{"key":"10.1016\/j.jacc.2021.12.032_bib2","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1194\/jlr.R060582","article-title":"Lipoprotein (a): truly a direct prothrombotic factor in cardiovascular disease?","volume":"57","author":"Boffa","year":"2016","journal-title":"J\u00a0Lipid Res"},{"key":"10.1016\/j.jacc.2021.12.032_bib3","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1016\/j.jacc.2016.11.042","article-title":"A\u00a0test in context: lipoprotein(a): diagnosis, prognosis, controversies, and emerging therapies","volume":"69","author":"Tsimikas","year":"2017","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2021.12.032_bib4","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1001\/jama.2009.1063","article-title":"for the Emerging Risk Factors Collaboration. Lipoprotein(a) concentration and the risk of coronary heart disease, stroke, and nonvascular mortality","volume":"302","author":"Erqou","year":"2009","journal-title":"JAMA"},{"key":"10.1016\/j.jacc.2021.12.032_bib5","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1161\/ATVBAHA.120.315291","article-title":"Lp(a) (Lipoprotein[a]) Concentrations and Incident Atherosclerotic Cardiovascular Disease: New Insights From a Large National Biobank","volume":"41","author":"Patel","year":"2021","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.jacc.2021.12.032_bib6","doi-asserted-by":"crossref","first-page":"1483","DOI":"10.1161\/CIRCULATIONAHA.118.037184","article-title":"Lipoprotein(a), PCSK9 Inhibition, and cardiovascular risk","volume":"139","author":"O'Donoghue","year":"2019","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2021.12.032_bib7","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/j.jacc.2019.10.057","article-title":"Effect of alirocumab on lipoprotein(a) and cardiovascular risk after acute coronary syndrome","volume":"75","author":"Bittner","year":"2020","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2021.12.032_bib8","doi-asserted-by":"crossref","first-page":"4245","DOI":"10.1093\/eurheartj\/ehaa649","article-title":"Lipoprotein(a) lowering by alirocumab reduces the total burden of cardiovascular events independent of low-density lipoprotein cholesterol lowering: ODYSSEY OUTCOMES trial","volume":"41","author":"Szarek","year":"2020","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jacc.2021.12.032_bib9","doi-asserted-by":"crossref","first-page":"1576","DOI":"10.1016\/j.jacc.2021.01.051","article-title":"Emerging RNA therapeutics to lower blood levels of Lp(a): JACC Focus Seminar 2\/4","volume":"77","author":"Tsimikas","year":"2021","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2021.12.032_bib10","doi-asserted-by":"crossref","first-page":"1472","DOI":"10.1016\/S0140-6736(15)61252-1","article-title":"Antisense therapy targeting apolipoprotein(a): a randomised, double-blind, placebo-controlled phase 1 study","volume":"386","author":"Tsimikas","year":"2015","journal-title":"Lancet"},{"key":"10.1016\/j.jacc.2021.12.032_bib11","doi-asserted-by":"crossref","first-page":"2239","DOI":"10.1016\/S0140-6736(16)31009-1","article-title":"Antisense oligonucleotides targeting apolipoprotein(a) in people with raised lipoprotein(a): two randomised, double-blind, placebo-controlled, dose-ranging trials","volume":"388","author":"Viney","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.jacc.2021.12.032_bib12","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1056\/NEJMoa1905239","article-title":"Lipoprotein(a) reduction in persons with cardiovascular disease","volume":"382","author":"Tsimikas","year":"2020","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jacc.2021.12.032_bib13","doi-asserted-by":"crossref","first-page":"2230","DOI":"10.1194\/jlr.M800174-JLR200","article-title":"A\u00a0novel function of lipoprotein [a] as a preferential carrier of oxidized phospholipids in human plasma","volume":"49","author":"Bergmark","year":"2008","journal-title":"J\u00a0Lipid Res"},{"key":"10.1016\/j.jacc.2021.12.032_bib14","doi-asserted-by":"crossref","first-page":"2815","DOI":"10.1194\/jlr.M040733","article-title":"Determinants of binding of oxidized phospholipids on apolipoprotein (a) and lipoprotein (a)","volume":"54","author":"Leibundgut","year":"2013","journal-title":"J\u00a0Lipid Res"},{"key":"10.1016\/j.jacc.2021.12.032_bib15","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1194\/jlr.R052258","article-title":"Antisense inhibition of apolipoprotein (a) to lower plasma lipoprotein (a) levels in humans","volume":"57","author":"Graham","year":"2016","journal-title":"J\u00a0Lipid Res"},{"key":"10.1016\/j.jacc.2021.12.032_bib16","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1097\/MOL.0000000000000171","article-title":"'LDL-C'\u00a0=\u00a0LDL-C\u00a0+ Lp(a)-C: implications of achieved ultra-low LDL-C levels in the proprotein convertase subtilisin\/kexin type 9 era of potent LDL-C lowering","volume":"26","author":"Yeang","year":"2015","journal-title":"Curr Opin Lipidol"},{"key":"10.1016\/j.jacc.2021.12.032_bib17","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.atherosclerosis.2020.03.003","article-title":"The dedicated \u201cLp(a) clinic\u201d: a concept whose time has arrived?","volume":"300","author":"Tsimikas","year":"2020","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.jacc.2021.12.032_bib18","series-title":"Genetics of Coronary Heart Disease","first-page":"75","year":"1992"},{"key":"10.1016\/j.jacc.2021.12.032_bib19","first-page":"151","article-title":"Incidence of Lp (a) lipoprotein among populations","author":"Dahl\u00e9n","year":"1990"},{"key":"10.1016\/j.jacc.2021.12.032_bib20","doi-asserted-by":"crossref","first-page":"100053","DOI":"10.1016\/j.jlr.2021.100053","article-title":"Novel method for quantification of lipoprotein(a)-cholesterol: implications for improving accuracy of LDL-C measurements","volume":"62","author":"Yeang","year":"2021","journal-title":"J\u00a0Lipid Res"},{"key":"10.1016\/j.jacc.2021.12.032_bib21","doi-asserted-by":"crossref","first-page":"3164","DOI":"10.1161\/01.CIR.0000130844.01174.55","article-title":"Percutaneous coronary intervention results in acute increases in oxidized phospholipids and lipoprotein(a): short-term and long-term immunologic responses to oxidized low-density lipoprotein","volume":"109","author":"Tsimikas","year":"2004","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2021.12.032_bib22","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1016\/j.clinbiochem.2004.02.001","article-title":"Electrophoretic measurement of lipoprotein(a) cholesterol in plasma with and without ultracentrifugation: comparison with an immunoturbidimetric lipoprotein(a) method","volume":"37","author":"Baudhuin","year":"2004","journal-title":"Clin Biochem"},{"key":"10.1016\/j.jacc.2021.12.032_bib23","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1056\/NEJMoa043175","article-title":"Oxidized phospholipids, Lp(a) lipoprotein, and coronary artery disease","volume":"353","author":"Tsimikas","year":"2005","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jacc.2021.12.032_bib24","article-title":"Low-density lipoprotein cholesterol corrected for lipoprotein(a) cholesterol, risk thresholds, and cardiovascular events","volume":"9","author":"Willeit","year":"2020","journal-title":"J\u00a0Am Heart Assoc"},{"key":"10.1016\/j.jacc.2021.12.032_bib25","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1016\/j.atherosclerosis.2021.03.036","article-title":"Prevalence and influence of LPA gene variants and isoform size on the Lp(a)-lowering effect of pelacarsen","volume":"324","author":"Karwatowska-Prokopczuk","year":"2021","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.jacc.2021.12.032_bib26","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1161\/ATVBAHA.120.314965","article-title":"Genome-Wide Association Study Highlights APOH as a Novel Locus for Lipoprotein(a) Levels-Brief Report","volume":"41","author":"Hoekstra","year":"2021","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.jacc.2021.12.032_bib27","doi-asserted-by":"crossref","first-page":"1267","DOI":"10.1016\/S0140-6736(05)67394-1","article-title":"Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins","volume":"366","author":"Baigent","year":"2005","journal-title":"Lancet"},{"key":"10.1016\/j.jacc.2021.12.032_bib28","doi-asserted-by":"crossref","first-page":"1783","DOI":"10.1016\/j.cca.2011.05.036","article-title":"Lipoprotein(a)-cholesterol: a significant component of serum cholesterol","volume":"412","author":"Kinpara","year":"2011","journal-title":"Clin Chim Acta"},{"key":"10.1016\/j.jacc.2021.12.032_bib29","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1016\/j.metabol.2004.10.001","article-title":"The metabolism of apolipoproteins (a) and B-100 within plasma lipoprotein (a) in human beings","volume":"54","author":"Jenner","year":"2005","journal-title":"Metabolism"},{"key":"10.1016\/j.jacc.2021.12.032_bib30","doi-asserted-by":"crossref","first-page":"950","DOI":"10.1172\/JCI110849","article-title":"Receptor-mediated catabolism of low density lipoprotein in man. Quantitation using glucosylated low density lipoprotein","volume":"71","author":"Kesaniemi","year":"1983","journal-title":"J\u00a0Clin Invest"},{"key":"10.1016\/j.jacc.2021.12.032_bib31","doi-asserted-by":"crossref","first-page":"1403","DOI":"10.1172\/JCI117794","article-title":"The low density lipoprotein receptor is not required for normal catabolism of Lp(a) in humans","volume":"95","author":"Rader","year":"1995","journal-title":"J\u00a0Clin Invest"},{"key":"10.1016\/j.jacc.2021.12.032_bib32","doi-asserted-by":"crossref","first-page":"1770","DOI":"10.1161\/ATVBAHA.117.309549","article-title":"CETP (Cholesteryl Ester Transfer Protein) inhibition with anacetrapib decreases production of lipoprotein(a) in mildly hypercholesterolemic subjects","volume":"37","author":"Thomas","year":"2017","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.jacc.2021.12.032_bib33","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1161\/ATVBAHA.116.308704","article-title":"Lipoprotein(a) mass levels increase significantly according to apoe genotype: an analysis of 431 239 patients","volume":"37","author":"Moriarty","year":"2017","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.jacc.2021.12.032_bib34","doi-asserted-by":"crossref","first-page":"154221","DOI":"10.1016\/j.metabol.2020.154221","article-title":"PCSK9 Inhibition with alirocumab increases the catabolism of lipoprotein(a) particles in statin-treated patients with elevated lipoprotein(a)","volume":"107","author":"Watts","year":"2020","journal-title":"Metabolism"},{"key":"10.1016\/j.jacc.2021.12.032_bib35","doi-asserted-by":"crossref","first-page":"2275","DOI":"10.1093\/eurheartj\/ehz310","article-title":"Statin therapy increases lipoprotein(a) levels","volume":"41","author":"Tsimikas","year":"2020","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jacc.2021.12.032_bib36","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1016\/j.jacl.2018.02.014","article-title":"Relationship between \u201cLDL-C,\u201d estimated true LDL-C, apolipoprotein B-100, and PCSK9 levels following lipoprotein(a) lowering with an antisense oligonucleotide","volume":"12","author":"Viney","year":"2018","journal-title":"J\u00a0Clin Lipidol"}],"container-title":["Journal of the American College of Cardiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0735109722001644?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0735109722001644?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T13:47:52Z","timestamp":1760017672000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0735109722001644"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,3]]},"references-count":36,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2022,3]]}},"alternative-id":["S0735109722001644"],"URL":"https:\/\/doi.org\/10.1016\/j.jacc.2021.12.032","relation":{},"ISSN":["0735-1097"],"issn-type":[{"value":"0735-1097","type":"print"}],"subject":[],"published":{"date-parts":[[2022,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Effect of Pelacarsen on Lipoprotein(a) Cholesterol and Corrected Low-Density Lipoprotein Cholesterol","name":"articletitle","label":"Article Title"},{"value":"Journal of the American College of Cardiology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jacc.2021.12.032","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 The Authors. Published by Elsevier on behalf of the American College of Cardiology Foundation.","name":"copyright","label":"Copyright"}]}}